TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors

Clinical trial NCT00543725 · COMPLETED

Trial details

NCT number: NCT00543725
Sponsor: Tibotec Pharmaceuticals, Ireland
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

HIV Infections HIV-1

Start date: 2008-06-01
Primary completion: 2010-01-01
Enrollment: 680

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.